Literature DB >> 2472397

Mapping of a putative surface-binding site of human coagulation factor XII.

B J Clarke1, H C Côté, D E Cool, I Clark-Lewis, H Saito, R A Pixley, R W Colman, R T MacGillivray.   

Abstract

We have localized the binding epitope(s) of two murine monoclonal antibodies (B7C9 and P5-2-1) that were shown previously to inhibit the activation of human coagulation factor XII by negatively charged surfaces. A factor XII cDNA expression library in lambda gt11 was screened with antibody B7C9, and 16 immunoreactive bacteriophage were isolated. Fusion proteins from each of the recombinant phage were reactive with both monoclonal antibodies. Two of the phage cDNA inserts were found to code for amino acid residues -6-+31 and +1-+47 of factor XII, respectively, thereby defining the limits of the antigenic peptide to amino acids +1-+31. Each of the remaining 14 recombinant phage contained longer factor XII cDNA inserts that included sequences coding for the amino-terminal 31 amino acid residues. These results were confirmed by direct binding of antibody B7C9 to synthetic peptides containing amino acids 1-14 and 1-28 of factor XII. Further experiments with a set of nested peptides also indicated that amino acid residues 1-4 were essential but not sufficient for binding of B7C9 to the peptides. Hydrophobicity analysis of the amino-terminal region of plasma factor XII revealed a highly hydrophilic region between amino acid residues 5 and 15 that contained positively charged lysine residues at positions 8, 11, and 13. We conclude that a major epitope(s) recognized by monoclonal antibodies B7C9 and P5-2-1 is present in the amino-terminal 28 amino acids of factor XII. It is proposed that binding of these antibodies to factor XII blocks interaction of the positively charged region between residues 5 and 15 with negatively charged surfaces, thereby inhibiting activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472397

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 3.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

4.  The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS.

Authors:  D X Beringer; L M J Kroon-Batenburg
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-26

5.  Anti-Factor XII Autoantibodies in Patients with Recurrent Pregnancy Loss Recognize the Second Epidermal Growth Factor-Like Domain.

Authors:  Yoshihiro Sato; Toshitaka Sugi; Rie Sakai
Journal:  TH Open       Date:  2019-09-03

6.  Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains.

Authors:  Aleksandr Shamanaev; Ivan Ivanov; Mao-Fu Sun; Maxim Litvak; Priyanka Srivastava; Bassem M Mohammed; Rabia Shaban; Ashoka Maddur; Ingrid M Verhamme; Owen J T McCarty; Ruby H P Law; David Gailani
Journal:  Blood Adv       Date:  2022-05-24

Review 7.  Factor XII in inflammation and wound healing.

Authors:  Evi X Stavrou
Journal:  Curr Opin Hematol       Date:  2018-09       Impact factor: 3.218

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.